- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00922623
Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VI
April 19, 2013 updated by: Merz North America, Inc.
A Multicenter Study of The Safety and Effectiveness of Dermal Filler, Belotero®, After Mid-to-Deep Dermal Implantation for Correction of Moderate to Severe Facial Wrinkles (Such as Nasolabial Folds) Over 24 Weeks in Subjects With Fitzpatrick Phototype Scores of IV, V, and VI.
This is a study to assess how safe and effective an investigational product, Belotero® is in people with all skin types with facial wrinkles, such as nasolabial folds.
Nasolabial folds are wrinkles on the face that go from outside of the nostrils to the edges of the mouth.
Study Overview
Detailed Description
The Fitzpatrick Skin Phototype Scale goes from number 1 (I), which is the very lightest skin tone, to number 6 (VI) which is the very darkest skin tone.
This study is to determine the safety and effectiveness of Belotero® in people with skin phototypes of 1(I)thru 6 (VI).
Study Type
Interventional
Enrollment (Actual)
93
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90036
- Pearl E Grimes
-
-
Maryland
-
Mitchellville, Maryland, United States, 20721
- Valerie Callender
-
-
New Jersey
-
Montclair, New Jersey, United States, 07042
- Jeanine B Downie
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Had reviewed and signed a statement of Informed Consent and HIPAA authorization. In addition, subjects were asked to provide a separate release for use of their photographs in publications. Subjects had a right to refuse the photo release without jeopardizing their eligibility to participate in the study.
- Was 18 to 75 years of age, of any race or sex.
- If female, was post-menopausal for at least one year; or had undergone a hysterectomy; or a tubal ligation; or if of childbearing potential, had negative urine pregnancy test results and agreed to use an approved method of birth control throughout the study (ie, oral/systemic contraceptives, intrauterine device [IUD], or spermicide in combination with a barrier method of contraception), or was abstinent, or was in a monogamous relationship with a partner who had had a vasectomy.
- Had bilateral nasolabial folds with a severity of 2 or 3 on the wrinkle severity rating scale (SRS) as assessed by the Evaluator Investigator.
- Subjects were to have been rated IV, V, or VI on the Fitzpatrick Skin Phototype Scale.
- Had adequate understanding of the language (spoken and written English or Spanish) and was willing to comply with the study requirements.
Exclusion Criteria:
- A personal history of allergic/anaphylactic reactions including hypersensitivity to local anesthetics (eg, lidocaine, etc), hyaluronic acid (HA) preparations, and/or gram-positive bacterial protein.
- A known history of keloids or bleeding disorders.
- Leukoderma (vitiligo) or a family history of leukoderma or other pigmentary disorders.
- An active inflammatory process in the nasolabial fold area (skin eruptions such as cysts, pimples, rashes, cancerous/pre-cancerous lesions, psoriasis, neurodermatitis, or any other active skin disease) or severe scarring that might interfere with study assessments.
- If female, pregnant, planning to become pregnant during the study, or breast feeding.
- Planned to undergo major facial surgery during the course of the study (eg, rhinoplasty [with or without implant], facelift, congenital defect repair, etc).
- Clinically important disease, as judged by the investigator, within 3 months of the study (eg, significant laboratory test abnormalities, myocardial infarct, stroke, cancer, connective tissue diseases [scleroderma, systemic lupus erythematous], systemic infection, uncontrolled diabetes, etc.), including those with medical conditions that might require the use of immunosuppressive medications during the trial (eg, severe, uncontrolled asthma, rheumatoid arthritis, autoimmune diseases, etc).
- Severe physical, neurological or mental disease.
- Excessive facial hair that might interfere with the evaluation of the wrinkle assessments.
- Any systemic or dermatologic disorder, which, in the opinion of the investigator, would interfere with the study results or increase the risk of AEs.
- Had used exclusionary medications/treatments.
- Participation in a clinical investigation within the 30 days prior to the first planned device administration or during this trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Belotero®
|
Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With Product-related Adverse Events.
Time Frame: 24 weeks
|
Adverse events considered possibly, probably, or definitely related to study product are summarized by body system and MedDRA preferred term.
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2009
Primary Completion (ACTUAL)
July 1, 2010
Study Completion (ACTUAL)
July 1, 2010
Study Registration Dates
First Submitted
June 3, 2009
First Submitted That Met QC Criteria
June 12, 2009
First Posted (ESTIMATE)
June 17, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
April 26, 2013
Last Update Submitted That Met QC Criteria
April 19, 2013
Last Verified
April 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MUS 90028-0622/1 Supplement
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Facial Wrinkles
-
The Plastic Surgery FoundationCompletedFacial Photo Damage | Periocular Fine Wrinkles | Perioral Fine WrinklesUnited States
-
Genzyme, a Sanofi CompanyInamed AestheticsCompleted
-
DeYi Aesthetic Medical ClinicNot yet recruiting
-
Genzyme, a Sanofi CompanyCompleted
-
PollogenUnknownFacial WrinklesUnited States
-
ConturaCompletedFacial WrinklesUnited States
-
YMD Eye and FaceCompletedFacial WrinklesUnited States
-
Merz North America, Inc.CompletedFacial WrinklesUnited States
-
Merz North America, Inc.CompletedFacial WrinklesUnited States
-
Catalysis SLCompleted
Clinical Trials on Belotero®
-
Merz North America, Inc.CompletedFacial WrinklesUnited States
-
Merz North America, Inc.CompletedFacial WrinklesUnited States
-
AllerganCompletedPatients With Moderate to Severe Perioral LinesUnited States
-
Merz North America, Inc.CompletedCorrection of Volume Loss in the Infraorbital Hollow AreaUnited States
-
Merz North America, Inc.CompletedCorrection of Moderate to Severe Nasolabial FoldsUnited States
-
Skin Care and Laser Physicians of Beverly HillsMerz Aesthetics Inc.UnknownRhytidosis FacialisUnited States
-
The Maas ClinicUnknownPerioral RhytidsUnited States
-
[Redacted]WithheldLip AugmentationUnited States, Puerto Rico
-
Merz North America, Inc.CompletedVolume Loss in the Infraorbital Hollow AreaUnited States, Puerto Rico